Benitec Biopharma Priced, Nasdaq: BNTC

Developing a gene therapy platform based on DNA-directed RNA interference.

Industry: Health Care

Latest Trade: $2.56 0.00 (0.0%)

First Day Return: -13.5%

Return from IPO: -72.2%

Industry: Health Care

We are a clinical-stage biotechnology company with a pipeline of in-house and partnered therapeutic programs based on our patented gene-silencing technology, ddRNAi. We are developing treatments for chronic and life-threatening human diseases such as hepatitis C, hepatitis B, age-related macular degeneration, drug-resistant non-small cell lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, we have licensed ddRNAi technology to other biopharmaceutical companies that are progressing their programs towards, or are in, clinical development for applications, including HIV/AIDS, retinitis pigmentosa, Huntington’s disease, cancer immunotherapy and intractable neuropathic pain.
more less
IPO News for Benitec Biopharma
more
IPO Data
IPO File Date 06/22/2015
Offer Price $9.21
Price Range $10.00 - $10.00
Offer Shares (mm) 1.5
Deal Size ($mm) $14
IPO Data
IPO Date 08/18/2015
Offer Price $9.21
Price Range $10.00 - $10.00
Offer Shares (mm) 1.5
Deal Size ($mm) $14
Underwriters
more
Company Data
Headquarters Balmain, Australia
Founded 1995
Employees 21
Website www.benitec.com